Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$5.03 -5.3%	$4.20	$1.48 ▼ $5.98	$472.61M	0.88	1.18 million shs	15.78 million shs
HRMY Harmony Biosciences	$31.98 +0.4%	$32.85	$26.47 ▼ $41.61	$1.83B	0.87	629,602 shs	1.45 million shs
IRON Disc Medicine	$54.50 +0.7%	$48.47	$30.82 ▼ $68.73	$1.87B	0.73	345,951 shs	1.06 million shs
TARS Tarsus Pharmaceuticals	$40.35 +0.0%	$44.24	$20.08 ▼ $57.28	$1.69B	0.83	698,446 shs	951,826 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	-5.27%	-3.64%	+19.76%	+60.70%	+502,999,900.00%
HRMY Harmony Biosciences	+0.38%	+0.28%	-5.16%	-3.65%	+2.90%
IRON Disc Medicine	+0.68%	+5.60%	+20.79%	+4.09%	+25.55%
TARS Tarsus Pharmaceuticals	+0.05%	-0.74%	-4.04%	-22.01%	+59.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.715 of 5 stars	3.6	2.0	3.2	1.7	0.6
HRMY Harmony Biosciences	4.7724 of 5 stars	4.6	1.0	2.9	3.3	4.4
IRON Disc Medicine	1.8127 of 5 stars	3.5	1.0	1.6	2.5	0.0
TARS Tarsus Pharmaceuticals	1.937 of 5 stars	3.5	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.14	Buy	$20.20	301.59% Upside
HRMY Harmony Biosciences	3.13	Buy	$53.63	67.68% Upside
IRON Disc Medicine	3.09	Buy	$96.70	77.43% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	65.22% Upside

Current Analyst Ratings Breakdown

Latest ATYR, HRMY, IRON, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	1,946.39	N/A	N/A	$0.83 per share	6.06
HRMY Harmony Biosciences	$714.73M	2.57	$2.96 per share	10.81	$11.56 per share	2.77
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
TARS Tarsus Pharmaceuticals	$182.95M	9.27	N/A	N/A	$5.87 per share	6.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.81	N/A	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	12.21	10.28	0.47	20.53%	24.32%	15.92%	8/5/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.73	N/A	N/A	N/A	-44.91%	-39.72%	-25.74%	8/6/2025 (Estimated)

Latest ATYR, HRMY, IRON, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	7.79	7.79
HRMY Harmony Biosciences	0.22	3.67	3.63
IRON Disc Medicine	0.04	37.65	37.65
TARS Tarsus Pharmaceuticals	0.21	5.57	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
HRMY Harmony Biosciences	86.23%
IRON Disc Medicine	83.70%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
HRMY Harmony Biosciences	23.60%
IRON Disc Medicine	4.24%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	38.25 million	Optionable

ATYR, HRMY, IRON, and TARS Headlines

Recent News About These Companies

Brokerages Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $66.67

June 20, 2025 | americanbankingnews.com

Tarsus Pharmaceuticals Becomes Oversold (TARS)

June 19, 2025 | nasdaq.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Brokerages

June 17, 2025 | marketbeat.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Assenagon Asset Management S.A. Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 12, 2025 | marketbeat.com

E. Ohman J or Asset Management AB Boosts Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 7, 2025 | marketbeat.com

Squarepoint Ops LLC Sells 51,329 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 7, 2025 | marketbeat.com

Stocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS Rating

June 6, 2025 | msn.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Time to Sell?

June 5, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 5, 2025 | marketbeat.com

Wellington Management Group LLP Sells 8,552 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

June 4, 2025 | marketbeat.com

Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer

June 2, 2025 | msn.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Oppenheimer

June 2, 2025 | marketbeat.com

Nuveen Asset Management LLC Sells 15,186 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 31, 2025 | marketbeat.com

Q2 Earnings Forecast for TARS Issued By HC Wainwright

May 30, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Ameriprise Financial Inc.

May 30, 2025 | marketbeat.com

Tarsus to Participate in Upcoming Investor Conferences

May 29, 2025 | globenewswire.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Lessened by Two Sigma Advisers LP

May 29, 2025 | marketbeat.com

Two Sigma Investments LP Has $5.05 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

May 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Tech Stocks You Can't Miss in This Market Cycle
By Gabriel Osorio-Mazilli | June 17, 2025
View 3 Tech Stocks You Can't Miss in This Market Cycle
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

ATYR, HRMY, IRON, and TARS Company Descriptions

aTyr Pharma NASDAQ:ATYR

$5.03 -0.28 (-5.27%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.09 +0.06 (+1.19%)

As of 06/27/2025 07:59 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Harmony Biosciences NASDAQ:HRMY

$31.98 +0.12 (+0.38%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$31.98 0.00 (0.00%)

As of 06/27/2025 07:53 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Disc Medicine NASDAQ:IRON

$54.50 +0.37 (+0.68%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$54.49 -0.01 (-0.02%)

As of 06/27/2025 05:59 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Tarsus Pharmaceuticals NASDAQ:TARS

$40.35 +0.02 (+0.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$40.35 +0.00 (+0.01%)

As of 06/27/2025 05:31 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time